Veterans Affairs Boston Healthcare System, Boston, Massachusetts.
Department of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts.
JAMA Cardiol. 2023 Jun 1;8(6):564-574. doi: 10.1001/jamacardio.2023.0857.
IMPORTANCE: Primary prevention of atherosclerotic cardiovascular disease (ASCVD) relies on risk stratification. Genome-wide polygenic risk scores (PRSs) are proposed to improve ASCVD risk estimation. OBJECTIVE: To determine whether genome-wide PRSs for coronary artery disease (CAD) and acute ischemic stroke improve ASCVD risk estimation with traditional clinical risk factors in an ancestrally diverse midlife population. DESIGN, SETTING, AND PARTICIPANTS: This was a prognostic analysis of incident events in a retrospectively defined longitudinal cohort conducted from January 1, 2011, to December 31, 2018. Included in the study were adults free of ASCVD and statin naive at baseline from the Million Veteran Program (MVP), a mega biobank with genetic, survey, and electronic health record data from a large US health care system. Data were analyzed from March 15, 2021, to January 5, 2023. EXPOSURES: PRSs for CAD and ischemic stroke derived from cohorts of largely European descent and risk factors, including age, sex, systolic blood pressure, total cholesterol, high-density lipoprotein (HDL) cholesterol, smoking, and diabetes status. MAIN OUTCOMES AND MEASURES: Incident nonfatal myocardial infarction (MI), ischemic stroke, ASCVD death, and composite ASCVD events. RESULTS: A total of 79 151 participants (mean [SD] age, 57.8 [13.7] years; 68 503 male [86.5%]) were included in the study. The cohort included participants from the following harmonized genetic ancestry and race and ethnicity categories: 18 505 non-Hispanic Black (23.4%), 6785 Hispanic (8.6%), and 53 861 non-Hispanic White (68.0%) with a median (5th-95th percentile) follow-up of 4.3 (0.7-6.9) years. From 2011 to 2018, 3186 MIs (4.0%), 1933 ischemic strokes (2.4%), 867 ASCVD deaths (1.1%), and 5485 composite ASCVD events (6.9%) were observed. CAD PRS was associated with incident MI in non-Hispanic Black (hazard ratio [HR], 1.10; 95% CI, 1.02-1.19), Hispanic (HR, 1.26; 95% CI, 1.09-1.46), and non-Hispanic White (HR, 1.23; 95% CI, 1.18-1.29) participants. Stroke PRS was associated with incident stroke in non-Hispanic White participants (HR, 1.15; 95% CI, 1.08-1.21). A combined CAD plus stroke PRS was associated with ASCVD deaths among non-Hispanic Black (HR, 1.19; 95% CI, 1.03-1.17) and non-Hispanic (HR, 1.11; 95% CI, 1.03-1.21) participants. The combined PRS was also associated with composite ASCVD across all ancestry groups but greater among non-Hispanic White (HR, 1.20; 95% CI, 1.16-1.24) than non-Hispanic Black (HR, 1.11; 95% CI, 1.05-1.17) and Hispanic (HR, 1.12; 95% CI, 1.00-1.25) participants. Net reclassification improvement from adding PRS to a traditional risk model was modest for the intermediate risk group for composite CVD among men (5-year risk >3.75%, 0.38%; 95% CI, 0.07%-0.68%), among women, (6.79%; 95% CI, 3.01%-10.58%), for age older than 55 years (0.25%; 95% CI, 0.03%-0.47%), and for ages 40 to 55 years (1.61%; 95% CI, -0.07% to 3.30%). CONCLUSIONS AND RELEVANCE: Study results suggest that PRSs derived predominantly in European samples were statistically significantly associated with ASCVD in the multiancestry midlife and older-age MVP cohort. Overall, modest improvement in discrimination metrics were observed with addition of PRSs to traditional risk factors with greater magnitude in women and younger age groups.
重要性:动脉粥样硬化性心血管疾病(ASCVD)的一级预防依赖于风险分层。全基因组多基因风险评分(PRS)被提议用于改善 ASCVD 风险估计。 目的:确定冠状动脉疾病(CAD)和急性缺血性中风的全基因组 PRS 是否可以在一个具有多种祖先的中年人群中改善传统临床危险因素的 ASCVD 风险估计。 设计、地点和参与者:这是一项回顾性队列研究的预后分析,从 2011 年 1 月 1 日至 2018 年 12 月 31 日进行了事件的发病分析。纳入了 MVP(百万退伍军人计划)中的成年人,这些人在基线时无 ASCVD 且未使用他汀类药物,是一个拥有来自大型美国医疗保健系统的遗传、调查和电子健康记录数据的大型生物库。数据于 2021 年 3 月 15 日至 2023 年 1 月 5 日进行分析。 暴露因素:CAD 和缺血性中风的 PRS 源自主要为欧洲血统的队列和危险因素,包括年龄、性别、收缩压、总胆固醇、高密度脂蛋白胆固醇、吸烟和糖尿病状况。 主要结局和测量指标:非致命性心肌梗死(MI)、缺血性中风、ASCVD 死亡和复合 ASCVD 事件的发生。 结果:共纳入了 79151 名参与者(平均[标准差]年龄 57.8[13.7]岁;68503 名男性[86.5%])。该队列包括以下经过协调的遗传和种族分类的参与者:18505 名非西班牙裔黑人(23.4%)、6785 名西班牙裔(8.6%)和 53861 名非西班牙裔白人(68.0%),中位(5 至 95 百分位数)随访时间为 4.3(0.7-6.9)年。从 2011 年到 2018 年,观察到 3186 例 MI(4.0%)、1933 例缺血性中风(2.4%)、867 例 ASCVD 死亡(1.1%)和 5485 例复合 ASCVD 事件(6.9%)。CAD PRS 与非西班牙裔黑人(危险比[HR],1.10;95%置信区间[CI],1.02-1.19)、西班牙裔(HR,1.26;95%CI,1.09-1.46)和非西班牙裔白人(HR,1.23;95%CI,1.18-1.29)参与者的 MI 发病相关。中风 PRS 与非西班牙裔白人参与者的中风发病相关(HR,1.15;95%CI,1.08-1.21)。CAD 加中风联合 PRS 与非西班牙裔黑人(HR,1.19;95%CI,1.03-1.17)和非西班牙裔(HR,1.11;95%CI,1.03-1.21)参与者的 ASCVD 死亡相关。联合 PRS 也与所有祖裔群体的 ASCVD 复合事件相关,但在非西班牙裔白人群体中(HR,1.20;95%CI,1.16-1.24)比非西班牙裔黑人(HR,1.11;95%CI,1.05-1.17)和西班牙裔(HR,1.12;95%CI,1.00-1.25)参与者中更为显著。在男性(5 年风险>3.75%,0.38%;95%CI,0.07%-0.68%)、女性(6.79%;95%CI,3.01%-10.58%)、年龄大于 55 岁(0.25%;95%CI,0.03%-0.47%)和年龄 40 至 55 岁(1.61%;95%CI,-0.07%至 3.30%)的中危人群中,加入 PRS 后对传统风险模型的净重新分类改善程度适中。 结论和相关性:研究结果表明,主要源自欧洲样本的 PRS 与 MVP 中多种祖裔的中年和老年人群的 ASCVD 统计学显著相关。总体而言,随着 PRS 加入传统危险因素,区分度指标适度提高,女性和年轻年龄组的幅度更大。
JAMA Netw Open. 2024-3-4
JAMA Netw Open. 2024-4-1
Cureus. 2025-6-14
JAMA Netw Open. 2025-4-1
Nat Med. 2025-4-16
Pharmacogenomics. 2025
JAMA Netw Open. 2024-3-4